Viral vectors are technologies that are used to transmit genetic information into cells. In gene therapy, modified viruses are utilized as viral vectors to safeguard the new gene while delivering it to the gene cassette in target cells. Due to genetic engineering, the majority of critical genes in viral vectors are missing, hence viral vectors are frequently produced in culture using specific cells that provide the necessary viral proteins needed to properly package the therapeutic gene into virus particles. Viral vector manufacturing is a new field and high research is going on in the field. It is used in gene therapy and vaccine making. North America is the largest market for Viral Vector Manufacturing followed by Europe and the Asia Pacific.This growth is primarily driven by Need Of Viral Vector Manufacturing in Gene Therapy and Demand Of Viral Vectors in Vaccinology.
Globally, a noticeable market trend is evident Adoption Of New Techniques in Viral Vector Production Workflow. The Biotechnology sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Thermo Fisher Scientific (United States), Vibalogics (United States), Lonza (Switzerland), Merck (Germany), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (United States), Spark Therapeutics (United States), Oxford BioMedica (United Kingdom), CGT Catapult (United Kingdom) and Cobra Biologics (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
On 15th Jan 2021, Thermo Fisher Scientific Inc., the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading provider of services and technologies for the life sciences industry, announced that Thermo Fisher has completed the acquisition of Novasep's viral vector manufacturing business in Belgium, Henogen S.A., for approximately €725 million in cash. Novasep's viral vector production division provides biotechnology and major biopharma customers with contract manufacturing services for vaccines and medicines.
- Need Of Viral Vector Manufacturing in Gene Therapy
- Demand Of Viral Vectors in Vaccinology
- Adoption Of New Techniques in Viral Vector Production Workflow
- Talent Shortage in Viral Vector Manufacturing Market
OpportunitiesCovid-19 Pandemic Has Drastically Increased the Demand of Viral Vector Vaccines and Growing Investment in Medical Research Will Boost the Demand of Viral Vector Manufacturing
ChallengesComplex Nature of Viral Vector Manufacturing and Different Regulations About Viral Vector Manufacturing in Different Regions
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the ReportAMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Viral Vector Manufacturing Study Sheds Light on The Viral Vector Manufacturing Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Viral Vector Manufacturing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Viral Vector Manufacturing industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.
Frequently Asked Questions (FAQ):
1. What is the growth rate predicted for the Global Viral Vector Manufacturing Market?
The Viral Vector Manufacturing market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Viral Vector Manufacturing Market?
Top performing companies in the Global Viral Vector Manufacturing market are Thermo Fisher Scientific (United States), Vibalogics (United States), Lonza (Switzerland), Merck (Germany), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (United States), Spark Therapeutics (United States), Oxford BioMedica (United Kingdom), CGT Catapult (United Kingdom) and Cobra Biologics (United Kingdom), to name a few.
3. Which region dominated the worldwide market for Viral Vector Manufacturing in 2020?
North America is dominating the Viral Vector Manufacturing Market.